SBC Medical Group (NASDAQ:SBC) Issues Earnings Results, Beats Estimates By $0.01 EPS

SBC Medical Group (NASDAQ:SBC) issued its earnings results on Friday. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01, FiscalAI reports. SBC Medical Group had a net margin of 24.28% and a return on equity of 24.17%. The company had revenue of $39.57 million for the quarter, compared to analysts’ expectations of $45.19 million.

Here are the key takeaways from SBC Medical Group’s conference call:

• Average revenue per customer rebounded to $316 in Q4 (+11% YoY), and management says customer growth and improving unit economics are moving together—management views this as a potential inflection point for long‑term growth.
• Full‑year revenue declined 15% to $174 million, driven by 2024 restructuring and a fee‑structure change in April 2025, indicating material top‑line pressure despite operational actions.
• Profitability strengthened as net income rose 9% to $51 million, EPS increased 4% to $0.50, and EBITDA was $70 million with a 40.4% margin, largely due to the non‑recurrence of prior one‑time listing and revaluation costs.
• Management is rolling out strategic initiatives—SBC Wellness 2.0 (longevity + AI), a multi‑brand dermatology strategy, and early international moves (e.g., OrangeTwist)—which broaden addressable markets but are still early stage.
• Capital policy prioritizes growth and active M&A using abundant cash (with a flexible, approved share buyback program not yet executed), giving the company strategic optionality but no near‑term deployment specifics.

SBC Medical Group Stock Performance

Shares of NASDAQ:SBC traded down $0.06 during trading on Friday, hitting $3.74. The company’s stock had a trading volume of 7,082 shares, compared to its average volume of 29,365. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.10 and a quick ratio of 5.06. The firm has a market cap of $383.43 million, a price-to-earnings ratio of 9.11 and a beta of 1.19. The company has a 50-day moving average of $4.13 and a 200-day moving average of $4.05. SBC Medical Group has a 12 month low of $2.91 and a 12 month high of $5.75.

Insider Transactions at SBC Medical Group

In other SBC Medical Group news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.12, for a total transaction of $9,376,548.00. Following the completion of the sale, the chief executive officer directly owned 861,600 shares of the company’s stock, valued at approximately $1,826,592. This represents a 83.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 89.47% of the company’s stock.

Institutional Investors Weigh In On SBC Medical Group

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of SBC Medical Group by 37.6% during the 4th quarter. Geode Capital Management LLC now owns 262,043 shares of the company’s stock valued at $1,129,000 after acquiring an additional 71,664 shares during the period. Millennium Management LLC bought a new position in SBC Medical Group in the 3rd quarter worth $219,000. Charles Schwab Investment Management Inc. lifted its position in SBC Medical Group by 91.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 27,341 shares of the company’s stock valued at $118,000 after purchasing an additional 13,074 shares in the last quarter. New York State Common Retirement Fund purchased a new position in SBC Medical Group during the second quarter valued at $104,000. Finally, Barclays PLC grew its holdings in SBC Medical Group by 123.7% during the fourth quarter. Barclays PLC now owns 17,779 shares of the company’s stock valued at $77,000 after purchasing an additional 9,831 shares during the period. Institutional investors own 60.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SBC. Weiss Ratings reissued a “sell (d+)” rating on shares of SBC Medical Group in a report on Monday, December 29th. BTIG Research assumed coverage on SBC Medical Group in a research note on Friday, March 6th. They issued a “buy” rating and a $8.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.50.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.